

Interim Report Q1 2022

Webcast at 10:00 am CET

May 19, 2022



SCANDION
ONCOLOGY

Disclaimer

This presentation, which should be understood to include these slides, their contents or any part of them, any oral presentation, any question or answer session and any written or oral materials discussed or distributed during a company presentation (the "Presentation"), has been prepared by Scandion Oncology A/S ("Scandion Oncology" or the "Company"), to be used solely for a company presentation. The information contained in the Presentation is provided solely for this purpose.

This Presentation does not constitute or form part of, and should not be construed as, any offer, invitation, solicitation or recommendation to purchase, sell or subscribe for any securities in any jurisdiction. The Presentation is intended to present background information on the Company, its business and the industry in which it operates and is not intended to provide complete disclosure. The Company has not been, and will not be, registered under the United States Securities Act of 1933, as amended (the "Securities Act"), or under any of the relevant securities laws of any state or other jurisdiction of the United States of America.


Certain information contained herein has been obtained from published sources prepared by other parties that the Company has deemed to be relevant and trustworthy. No representation or warranty, express or implied, is made by the Company as to the accuracy, completeness or verification of any information contained in this Presentation. The Company has not made any independent review of information based on public statistics or information from an independent third party regarding the market information that has been provided by such third party, the industry or general publications.

Statements in this Presentation, including those regarding the possible or assumed future or other performance of the Company or its industry or other trend projections, constitute forward-looking statements. By their nature, forward-looking statements involve known and unknown risks, uncertainties, assumptions and other factors as they relate to events and depend on circumstances that will or may occur in the future, whether or not outside the control of the Company. No assurance is given that such forward-looking statements will prove to be correct. Past performance does not guarantee or predict future performance. Moreover, the Company does not – to the extent this is not required by law - undertake any obligation to review, update or confirm expectations or estimates or to release any revisions to any forward-looking statements to reflect events that occur or circumstances that arise in relation to the content of this Presentation.

This Presentation as well as any other information provided by or on behalf of the Company in connection herewith shall be governed by Danish law. The courts of Denmark, with the District Court of Copenhagen as the first instance, shall have exclusive jurisdiction to settle any conflict or dispute arising out of or in connection with this Presentation or related matters.

Agenda

- **Highlights from Q1, 2022**
- **Pipeline**
- **Financial Update Q1, 2022**
- **Outlook for 2022**
- **External Profiling**
- **Investment Highlights**



**Close to 10 million
people are dying
from cancer every
year**

**90% of cancer
deaths are due to
drug resistant
cancer cells**

Highlights from Q1, 2022

- January 12** Mads Kronborg appointed as Head of External Communication
- January 18** Data from the CORIST study with the Company's lead compound SCO-101 was accepted for poster presentation at the ASCO Gastrointestinal Cancers Symposium
- February 2** Scandion Oncology announced approval from the German and Spanish regulatory authorities to expand part 2 of the CORIST Phase II study to Germany and Spain
-
- May 11** Dr. Alfredo Zurlo appointed as new Chief Medical Officer



Dr. Alfredo Zurlo Appointed as New CMO at Scandion

- More than 20 years of experience in planning and conducting early and late-stage clinical programs in oncology
- Several global management positions at Roche, including serving as International Medical Director of Oncology and heading the launch of bevacizumab (Avastin) in Europe and the rest of the world for the colorectal cancer indication
- Following his tenure at Roche, he served as CMO in the two biotech companies Glycotope and Mologen
- In addition to his extensive strategic and operational clinical trial experience, he brings a large international network of health care professionals, research scientists and industry experts to Scandion



Pipeline

Developing first-in-class medicines for personalized therapy targeting cancer drug resistance

Program	Compound	Indication	Discovery / Pre-clinical	Phase I	Phase II	Phase III
CORIST	SCO-101	Colorectal cancer	SCO-101 + FOLFIRI			Read-out Q2-Q3, 2022
PANTAX	SCO-101	Pancreatic cancer	SCO-101 + nab-paclitaxel and gemcitabine			Read-out Q2-Q3, 2022
Immuno-oncology	SCO-101	Multiple cancers				
201	SCO-201	Solid tumors				



Financial Update Q1, 2022

Financial Overview

- Net result and cost in line with expectations
- Cost of the ongoing clinical studies CORIST and PANTAX progress as planned
- Strong cash position – financing outlook unchanged with cash to sustain operations into 2023

Financial summary DKK '000	Q1		Full year 2021
	2022	2021	
Other income	90	93	797
Research & development	-13,122	-7,998	-47,711
General & administration	-3,280	-1,999	-8,453
Financial items	-251	-1,350	-1,846
Tax	3,644	2,399	5,508
Net result	-12,919	-8,855	-51,705
Earnings per share (DKK)	-0.40	-0.28	-1.61
Cash position	87,965	145,216	105,710

Cash Position

Quarterly cash spend Q1
2022

16.4 MDKK


Cash position
March 31, 2022

88.0 MDKK



Financing of the Company's
operations into 2023

Operating Expenses 2020 - 2022



Progression of clinical studies

Cost of the ongoing clinical studies CORIST and PANTAX progress as planned

Expected Significant Events 2022

Q2-Q3 2022



CORIST

Data read-out part 2 of Phase II study

Q2-Q3 2022



PANTAX

Data read-out Phase Ib study

Financing secured into
2023

External Profiling

- **Upcoming Events**

- **Økonomisk Ugebrev Lifescience konference**, June 1, 2022
- **Redeye Growth Day**, June 2, 2022
- **BIO International Convention 2022**, June 13-16, 2022
- **Aktiespararna Småbolagsdagarna 2022**, June 14, 2022
- **EACR 2022**, June 20 -23, 2022
- **ChinaBIO Partnering Forum 2022**, September 13-16, 2022

- **Events in Q1, 2022**

- **Biotech Showcase at JPM**, January 10-12, 2022
- **Redeye Fight Cancer Seminar**, January 20, 2022
- **Edison Open House: Global Healthcare 2022**, January 25-27, 2022
- **Swiss Nordic Bio**, March 23, 2022



Why Invest in Scandion Oncology

We are first movers in cancer drug resistance

- We are first-in-class, targeting a gigantic market

High medical need and yet also an established market

- 10M cancer-related deaths annually
- SCO-101 has platform potential

De-risked clinical asset

- Near proof-of-concept and value-inflection
- Pivotal trial within reach in 2023

Highly focused pipeline and clinical development

- Focused early-stage pipeline for value creation
- Plethora of opportunities to broaden into other cancer indications

Run by seasoned leadership team

- Leadership team with a clear track record
- Best in class CAB
- Strong and well-connected BoD

Multiple value inflection points over the next few years

- PoC mCRC Phase II in Q2-Q3, 2022
- PDAC Phase Ib study read-out in Q2-Q3, 2022